Literature DB >> 19265855

Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction.

John A Taylor1, George A Kuchel.   

Abstract

The association between aging and cancer is well exemplified by bladder cancer: with advancing age, the risk of developing bladder cancer increases, and patients' clinical presentation and outcomes worsen. Care for elderly patients with bladder cancer requires specific knowledge of many key geriatric clinical issues in order to determine optimal treatment plans. While numerous studies have tried to address the role of urologic intervention for elderly patients with bladder cancer, many studies fail to incorporate a component of true functional assessment. Evaluation tools that incorporate comorbidities, disabilities and functional status will need to be developed, as chronological age is a poor predictor of treatment outcomes. Additionally, further research is necessary to better understand the basic mechanisms that predispose elderly patients to develop this costly and life-threatening disease. This Review examines the current literature evaluating the clinical and mechanistic interactions between aging and bladder cancer, and suggests the formulation of a research agenda to address the issues raised.

Entities:  

Mesh:

Year:  2009        PMID: 19265855      PMCID: PMC2957872          DOI: 10.1038/ncpuro1315

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  41 in total

Review 1.  Assessing decisional capacity in the elderly.

Authors:  Miriam B Rodin; Supriya G Mohile
Journal:  Semin Oncol       Date:  2008-12       Impact factor: 4.929

2.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.

Authors:  R Maruyama; S Toyooka; K O Toyooka; K Harada; A K Virmani; S Zöchbauer-Müller; A J Farinas; F Vakar-Lopez; J D Minna; A Sagalowsky; B Czerniak; A F Gazdar
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  Radical cystectomy in patients older than 75 years: assessment of morbidity and mortality.

Authors:  X Gamé; M Soulié; P Seguin; N Vazzoler; C Tollon; F Pontonnier; P Plante
Journal:  Eur Urol       Date:  2001-05       Impact factor: 20.096

4.  Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer.

Authors:  T Habuchi; T Takahashi; H Kakinuma; L Wang; N Tsuchiya; S Satoh; T Akao; K Sato; O Ogawa; M A Knowles; T Kato
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

5.  Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals.

Authors:  D M Bornman; S Mathew; J Alsruhe; J G Herman; E Gabrielson
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  Mutation frequency and specificity with age in liver, bladder and brain of lacI transgenic mice.

Authors:  G R Stuart; Y Oda; J G de Boer; B W Glickman
Journal:  Genetics       Date:  2000-03       Impact factor: 4.562

7.  A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer.

Authors:  Michel Soulié; Michael Straub; Xavier Gamé; Philippe Seguin; Robert De Petriconi; Pierre Plante; Richard E Hautmann
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

8.  Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.

Authors:  Brenda K Edwards; Holly L Howe; Lynn A G Ries; Michael J Thun; Harry M Rosenberg; Rosemary Yancik; Phyllis A Wingo; Ahmedin Jemal; Ellen G Feigal
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

9.  Radical cystectomy in the elderly patient.

Authors:  E C Skinner; G Lieskovsky; D G Skinner
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

10.  Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program.

Authors:  Badrinath R Konety; Sue A Joslyn
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

View more
  20 in total

1.  Influence of age on false positive rates of urine-based tumor markers.

Authors:  M Horstmann; T Todenhöfer; J Hennenlotter; S Aufderklamm; J Mischinger; U Kuehs; G Gakis; A Stenzl; C Schwentner
Journal:  World J Urol       Date:  2012-07-18       Impact factor: 4.226

2.  Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study.

Authors:  Chu-Wen Fang; Cheng-Hsi Liao; Shih-Chi Wu; Chih-Hsin Muo
Journal:  World J Urol       Date:  2018-02-09       Impact factor: 4.226

3.  Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.

Authors:  Shulin Wu; Sharron X Lin; Min Lu; Alexander O Subtelny; Zongwei Wang; Douglas M Dahl; Aria F Olumi; Chin-Lee Wu
Journal:  Int Urol Nephrol       Date:  2019-06-10       Impact factor: 2.370

4.  Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy.

Authors:  Zhongbo Liu; Xuesen Li; Anne R Simoneau; Mahtab Jafari; Xiaolin Zi
Journal:  Mol Carcinog       Date:  2011-04-22       Impact factor: 4.784

Review 5.  Bladder cancer, inflammageing and microbiomes.

Authors:  Austin Martin; Benjamin L Woolbright; Shahid Umar; Molly A Ingersoll; John A Taylor
Journal:  Nat Rev Urol       Date:  2022-07-07       Impact factor: 16.430

6.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

Review 7.  Advances in Research on Anticancer Properties of Salidroside.

Authors:  An-Qi Sun; Xiu-Lian Ju
Journal:  Chin J Integr Med       Date:  2020-03-06       Impact factor: 1.978

8.  Inhibiting invasion into human bladder carcinoma 5637 cells with diallyl trisulfide by inhibiting matrix metalloproteinase activities and tightening tight junctions.

Authors:  Dong Yeok Shin; Hee-Jae Cha; Gi-Young Kim; Wun-Jae Kim; Yung Hyun Choi
Journal:  Int J Mol Sci       Date:  2013-10-01       Impact factor: 5.923

9.  The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient.

Authors:  Ajay Gopalakrishna; Thomas A Longo; Joseph J Fantony; Richmond Owusu; Wen-Chi Foo; Rajesh Dash; Brant A Inman
Journal:  BMC Urol       Date:  2016-06-13       Impact factor: 2.264

10.  Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran.

Authors:  Hamid Mazdak; Zahra Tolou-Ghamari
Journal:  Arab J Urol       Date:  2018-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.